Inactive Instrument

Torii Pharmaceutical Co., Ltd.

4551

JP3635800000

Torii Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 7, 2025, has expired.

Published on 08/31/2025

S&P Capital IQ

TORII PHARMACEUTICAL CO., LTD.

+0.32%

JAPAN TOBACCO INC.

-0.86%

The company expired its plan on September 1, 2025.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	TORII PHARMACEUTICAL CO., LTD.	6,350.00JPY	+0.32%	+0.32%	1.17B
	JAPAN TOBACCO INC.	6,087.00JPY	-0.86%	+0.79%	71.51B

Latest news about Torii Pharmaceutical Co., Ltd.

31/08/25	Torii Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 7, 2025, has expired.	CI
10/07/25	Torii Pharmaceutical Co Ltd says it will retire treasury shares worth 2.39% of outstanding stock on Aug 29	RE
19/06/25	Shionogi Completes Tender Offer for Torii Pharmaceutical, Acquiring 39% Stake	MT
17/06/25	Shionogi & Co., Ltd. completed the acquisition of 44.1% stake in Torii Pharmaceutical Co., Ltd. from group of sellers.	CI
08/05/25	Japan's Nikkei ends higher; NTT Data surges on takeover report	RE
07/05/25	Shionogi to Acquire Japan Tobacco's Pharma Business, Take Full Control of Torii Pharmaceutical	MT
07/05/25	Deals of the day-Mergers and acquisitions	RE
07/05/25	Torii Pharmaceutical Co., Ltd. announces an Equity Buyback for 15,398,800 shares, representing 54.78% for ¥70,341.72 million.	CI
07/05/25	Deals of the day-Mergers and acquisitions	RE
07/05/25	Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion	RE
07/05/25	Shionogi & Co: To Launch Tender Offer For Torii Pharmaceutical Shares At 6,350 Yen Per Share	RE
07/05/25	Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion	RE
07/05/25	Shionogi To Buy Torii Pharmaceutical For About 150 Billion Yen, Nikkei Says	RE
06/05/25	Shionogi & Co., Ltd. proposed to acquire 44.1% stake in Torii Pharmaceutical Co., Ltd. from group of sellers for ¥80.7 billion.	CI
06/12/24	Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan	CI

Chart Torii Pharmaceutical Co., Ltd.

Duration

Period

4551: Dynamic Chart

TORII PHARMACEUTICAL CO., LTD. is mainly engaged in the manufacture and sale of pharmaceutical products. The Companyâ€™s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Companyâ€™s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.

Employees

592

Sector

Pharmaceuticals

Calendar

04-23 - Q1 2026 Earnings Release (Projected)

More about the company